Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Growth Metrics

Others

Ratios

Lyra Therapeutics (LYRA) Cash from Restructuring (2024 - 2025)

Lyra Therapeutics has reported Cash from Restructuring over the past 2 years, most recently at $207000.0 for Q4 2025.

Quarterly results put Cash from Restructuring at $207000.0 for Q4 2025, up 140.75% from a year ago — trailing twelve months through Dec 2025 was -$1.1 million (changed N/A YoY), and the annual figure for FY2025 was -$1.1 million, down 124.87%.
Cash from Restructuring for Q4 2025 was $207000.0 at Lyra Therapeutics, up from -$427000.0 in the prior quarter.
Over the last five years, Cash from Restructuring for LYRA hit a ceiling of $1.7 million in Q3 2024 and a floor of -$553000.0 in Q2 2025.